An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
St. Jude Medical, Inc., a global medical device company, today announced the results of the ASymptomatic AF and Stroke Evaluation in Pacemaker Patients and the AF Reduction Atrial Pacing Trial (ASSERT), a St. Jude Medical sponsored trial conducted by the Population Health Research Institute of McMaster University and Hamilton Health Sciences in Hamilton, Canada.
New techniques now being used at UCLA allow doctors to more precisely target certain areas of the heart to stop ventricular arrhythmias — serious abnormal rhythms in the heart's lower chambers — in high-risk patients.
CardioNet, Inc., a leading wireless medical technology company with an initial focus on the diagnosis and monitoring of cardiac arrhythmias, announced today that the Company entered into a definitive merger agreement with Biotel, Inc. to acquire all of the outstanding shares of Biotel for $11 million, or $3.84 per share, before adjustments for working capital. In connection with the merger agreement, the parties entered into a settlement agreement to dismiss the outstanding litigation between them, which will be effective as of the close of the merger.
Global Health Partner AB: Revenues increased by 17 percent to SEK 108.8 million (93.3). The operating result amounted to SEK -4.1 million (-13.1)
The Medical Practitioner's Board of Western Australia is looking into the case of a doctor and her role in an alternative cancer therapy program. Five cancer patients have died after apparently being given industrial solvents and dangerous minerals as a part of an alternative therapy program by Alexandra Boyd, a well-known Mosman Park breast cancer specialist. She along with two registered nurses administered the concoctions to the people in question.
Two new drugs have gained approval from the US Food and Drug Administration (FDA) – one is an antibiotic from Forest Labs and the other a first-time treatment for a neurological disorder developed by Avanir Pharmaceuticals. Another waiting for approval is Biodel's fast-acting insulin Linjeta. On the other hand seven new drugs got rejected including a diabetes drug from Amylin Pharmaceuticals and weight-loss drugs from Arena Pharmaceuticals and Vivus, respectively.
IntriCon Corporation a designer, developer, manufacturer and distributor of body-worn medical devices, today announced financial results for its third quarter ended September 30, 2010.
The Canadian Cardiovascular Society (CCS) presented its new 2010 Atrial Fibrillation Guidelines, the first update in six years, at the Canadian Cardiovascular Congress (CCC) in Montreal.
Boehringer Ingelheim Ltd. today announces that Health Canada has granted approval of PRADAX (dabigatran etexilate), an oral anticoagulant for the prevention of stroke and systemic embolism in adults with atrial fibrillation in whom anticoagulation is appropriate. PRADAX is the first innovative drug approved in Canada in more than two decades to reduce the risk of stroke in Canadians with atrial fibrillation.
The North American Center for Continuing Medical Education, LLC in partnership with HMP Communications, LLC, publisher of EP Lab Digest, today announced that the Electrophysiology Innovations Congress--EP Innovations 2010 will be co-sponsored by the Heart Rhythm Society. Electrophysiology Innovations Congress EP Innovations 2010, the world's premier annual electrophysiology meeting, will take place December 9-11, 2010, at the Washington Hilton in Washington, DC.
Summaries of a number of new Canadian Cardiovascular Society guidelines and position statements offering the most up to date information to support clinicians in practicing evidence-based medicine were released at the Canadian Cardiovascular Congress 2010 this week.
Levels of anxiety sensitivity may be important in choosing medical treatment for patients with heart failure and atrial fibrillation (AF), Montreal Heart Institute researchers today told the Canadian Cardiovascular Congress 2010, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society.
Stereotaxis, Inc. announced today that it launched the Odyssey Interventional Network, a training and educational video sharing web portal for the global cardiovascular community. The portal will showcase innovative electrophysiology (EP) and interventional cardiology (IC) procedures from leading centers around the world.
CyDex Pharmaceuticals, Inc. today announced a mutual decision with Prism Pharmaceuticals to terminate their existing joint development agreement on novel Captisol-enabled® intravenous formulations of clopidogrel. This provides CyDex with full development and commercialization rights to the product candidate - an injectable formulation of clopidogrel. Clopidogrel is the active ingredient in PLAVIX®, an orally available antiplatelet drug, which currently is marketed by Bristol-Myers Squibb Company and Sanofi-Aventis, Inc.
Magnetecs Corporation, a designer and manufacturer of robotic systems for minimally invasive surgical procedures, today reported that human studies have commenced using the Company's Catheter Guidance Control and Imaging (CGCI) system for patients with arrhythmia, or irregular heart beat.
In a powerful demonstration of collective standing in the health care community, more than 40 organizations gathered on Capitol Hill to issue a call to action in reducing sudden cardiac arrest (SCA) deaths.
Scientists at the University of Bonn have altered cardiac muscle cells to make them controllable with light. They were thus able to use directed light to cause conditions such as arrhythmia in genetically modified mice. The method opens up completely new possibilities for researching the development of such arrhythmias. The study will be published in the upcoming edition of "Nature Methods".
CardioDx, a pioneer in the field of cardiovascular genomic diagnostics, today announced publication of results from the Personalized Risk Evaluation and Diagnosis In the Coronary Tree (PREDICT) trial in the Annals of Internal Medicine, the journal of the American College of Physicians.
Estech, a leading provider of minimally invasive cardiac surgery devices, today announced the launch of its COBRA Revolution™ Bipolar Clamp for use in surgical ablation procedures. The new instrument enables deep transmural lesion formation after a single application and is the only clamp to feature reversible jaws, which uniquely allows surgeons to follow anatomic contours, for unprecedented ease of use and efficiency.
Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.